Premium
Methylenedioxypyrovalerone (MDPV): Self‐administration and acute drug challenges in rats
Author(s) -
Aarde Shawn M.,
Huang Pai-Kai,
Creehan Kevin M,
Vaillancourt Brittani D,
Vandewater Sophia A,
Wright Mayo J,
Miller Michelle L,
Taffe Michael A
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.1040.5
Subject(s) - stimulant , abuse liability , pharmacology , medicine , drugs of abuse , saline , bolus (digestion) , anesthesia , drug , fenfluramine , receptor , serotonin
Little is known regarding the abuse liability or the behavioral and physiological effects of MDPV. We present data on the effects of MDPV in rats from both intravenous self‐administration (IVSA) and acute drug challenge experiments. IVSA of MDPV was established on an FR5 schedule to stable intake patterns and high lever discrimination. Dose‐dependent rates of responding were observed under both FR and PR schedules wherein as per‐infusion dose increased, infusions decreased under FR but increased under PR. In acute challenge studies, bolus s.c. injections of MDPV showed a biphasic effect on both body temperature (compared to saline, low doses increased body temperature while high doses decreased body temperature) and activity counts (compared to saline, low doses increased activity while high doses suppressed activity). These initial data indicate that MDPV has an abuse liability that is similar to that of other stimulant drugs of abuse. Additionally, the observed biphasic effects in body temperature and activity may be related to the observed increase in stereotypy at higher doses of MDPV. (Grant DA024105).